Oceans BIo
AI-powered electroceuticals for treating neurological disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
Oceans BIo, founded in 2018 by CEO Lee Hyun-woong, is a South Korean medical technology company developing electroceutical devices for neurological and neuropsychological diseases. The company specializes in both non-invasive and implantable vagus nerve stimulation (VNS) devices, leveraging expertise in biomedical engineering, AI, and neuroscience.
The company's flagship product is the TaVNS (transcutaneous auricular vagus nerve stimulation), an earbud-type, non-invasive device designed for patients with conditions like depression and epilepsy. Its discreet design allows for use at any time and place, offering a significant advantage over traditional treatments. Oceans BIo is also developing an implantable VNS (iVNS) and plans to collect and analyze biological data to provide hyper-personalized treatment solutions.
Based in Changwon, with an R&D center in Seoul and a global office in New York, the company targets the electroceuticals market. Its business model focuses on the development and eventual sale of these medical devices upon completion of clinical trials and regulatory approval. The company has secured pre-Series A funding from investors including Seoul Techno Holdings Inc., Korea Credit Guarantee Fund, PNU Technology Holdings, and D.Camp to advance prototype development and clinical trials.
Keywords: electroceuticals, vagus nerve stimulation, VNS, medical devices, neurological disorders, depression treatment, epilepsy treatment, biomedical engineering, non-invasive treatment, TaVNS, implantable medical devices, personalized medicine, neurotechnology, medtech, AI in healthcare, neuropsychology, addiction treatment, bioelectronic medicine